Wiki rasagiline
< Rasagiline is used to treat symptoms of Parkinson’s disease both alone and in combination with other drugs. It has shown efficacy in both early and advanced Parkinson’s, and appears to be especially useful in dealing with non-motor symptoms like fatigue.[15][16][2]
< MAO-B inhibitors like rasagiline may improve certain non-motor symptoms in Parkinson’s disease.[19] These may include depression, sleep disturbances, and pain (particularly related to motor fluctuations), but are unlikely to include cognitive or olfactory dysfunctions
< Parkinson’s disease is characterized by the death of cells that produce dopamine, a neurotransmitter. An enzyme called monoamine oxidase (MAO) breaks down neurotransmitters. MAO has two forms, MAO-A and MAO-B. MAO-B is involved in the metabolism of dopamine. Rasagiline prevents the breakdown of dopamine by irreversibly binding to MAO-B. Dopamine is therefore more available, somewhat compensating for the diminished quantities made in the brains of people with Parkinson’s disease.
< In 2021, it was discovered that MAO-A is solely or almost entirely responsible for striatal dopamine catabolism in the rodent brain and that MAO-B is not importantly involved.[70][71][72] In contrast, MAO-B appears to mediate tonic γ-aminobutyric acid (GABA) synthesis from putrescine in the striatum, a minor and alternative metabolic pathway of GABA synthesis, and this synthesized GABA in turn inhibits dopaminergic neurons in this brain area
< Like rasagiline, 1-aminoindan shows neuroprotective activity in some experimental models.[1][56] In addition, 1-aminoindan has been found to enhance striatal dopaminergicneurotransmission and improve motor function independent of MAO inhibition in animal models of Parkinson’s disease.
< Rasagiline has been found to bind reversibly to α-synuclein, a major protein involved in the pathophysiology of Parkinson’s disease, and this action might be neuroprotective.[82][83][84]
< Pahwa and Lyons
Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Pasrkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10: 415–23.
Enzyme inhibitor https://en.wikipedia.org/wiki/Enzyme_inhibitor#Irreversible_inhibitors